林业发展局为Hodgkin Lymphoma的新的疗法指定了RMAT,显示有希望的早期结果。 FDA grants RMAT designation to a new therapy for Hodgkin Lymphoma, showing promising early results.

美国食品和药物管理局将抗逆转录病毒药物高级治疗(RMAT)指定为Affimed和Artiva生物治疗疗法的新组合疗法,用于治疗复发或复发性Hodgkin Lymphoma。 The U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to a new combination therapy by Affimed and Artiva Biotherapeutics for treating relapsed or refractory Hodgkin Lymphoma. 这种指定可以加快批准过程,并提供更强大的FDA支持. This designation can speed up the approval process and provides enhanced FDA support. 第二阶段试验的早期数据显示,患者总体答复率为83.3%,完全答复率为50%。 Early data from a phase 2 trial showed an 83.3% overall response rate and a 50% complete response rate in patients.